Journal ArticleDOI
Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management.
Reads0
Chats0
TLDR
A HER2 genetic examination by fluorescence in situ hybridization (FISH) of invasive breast cancers before and after taxane treatment found Thirty of 344 patients whose tumors were initially HER2-negative were found by FISH to have supernumerary HER2 gene copies after neoadjuvant chemotherapy.About:
This article is published in Cancer Genetics and Cytogenetics.The article was published on 2013-01-01. It has received 30 citations till now. The article focuses on the topics: Breast cancer & Primary tumor.read more
Citations
More filters
Journal ArticleDOI
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
TL;DR: The tremendous clinical success of checkpoint blockers illustrates the potential of reestablishing latent immunosurveillance for cancer therapy, and their in-depth comprehension will facilitate the design of novel combinatorial regimens with improved clinical efficacy.
Journal ArticleDOI
Linking cellular stress responses to systemic homeostasis
TL;DR: Cellular stress responses primarily serve to rectify stress-associated damage, but these responses are also coupled with the generation of various signals that are transmitted to the cellular microenvironments or even across tissues, which generally supports the maintenance of systemic homeostasis but can also result in pathology.
Journal ArticleDOI
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer : recommendations from an international working group
Elena Provenzano,Veerle Bossuyt,Giuseppe Viale,David Cameron,Sunil V. Badve,Carsten Denkert,Gaëtan MacGrogan,Frédérique Penault-Llorca,Judy C. Boughey,Giuseppe Curigliano,J. Michael Dixon,Laura J. Esserman,Gerd Fastner,Thorsten Kuehn,Florentia Peintinger,Gunter von Minckwitz,Julia White,Wei Yang,W. Fraser Symmans +18 more
TL;DR: Recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer specimens should improve prognostication for individual patients and allow comparison of treatment outcomes within and across clinical trials.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
Elena Provenzano,Veerle Bossuyt,Giuseppe Viale,David Cameron,Sunil V. Badve,Carsten Denkert,Gaëtan MacGrogan,Frédérique Penault-Llorca,Judy C. Boughey,Giuseppe Curigliano,J. Michael Dixon,Laura J. Esserman,Gerd Fastner,Thorsten Kuehn,Florentia Peintinger,Gunter von Minckwitz,Julia White,Wei Yang,W. Fraser Symmans +18 more
TL;DR: A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting as mentioned in this paper.
Journal ArticleDOI
Releasing Pressure in Tumors: What Do We Know So Far and Where Do We Go from Here? A Review
TL;DR: The methods to reduce tumor pressure that may open up new avenues in cancer treatment are explored, including irradiation, hyperbaric oxygen therapy, hyper- or hypothermic therapy, and photodynamic therapy.
References
More filters
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga,Javier Cortes,Sung-Bae Kim,Seock-Ah Im,Roberto Hegg,Young-Hyuck Im,L Roman,Jose Luiz Pedrini,Tadeusz Pienkowski,Adam Knott,Emma Clark,Mark C. Benyunes,Graham Ross,Sandra M. Swain +13 more
TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
Journal ArticleDOI
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo,Fred R. Hirsch,Elisa Rossi,Stefania Bartolini,Giovanni Luca Ceresoli,Lynne T. Bemis,Jerry Haney,Samir E. Witta,Kathleen D. Danenberg,I. Domenichini,Vienna Ludovini,Elisabetta Magrini,Vanesa Gregorc,Claudio Doglioni,Angelo Sidoni,Maurizio Tonato,Wilbur A. Franklin,Lucio Crinò,Paul A. Bunn,Marileila Varella-Garcia +19 more
TL;DR: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Journal ArticleDOI
Mitotic catastrophe: a mechanism for avoiding genomic instability
Ilio Vitale,Lorenzo Galluzzi,Lorenzo Galluzzi,Maria Castedo,Maria Castedo,Guido Kroemer,Guido Kroemer +6 more
TL;DR: The disruption of mitotic catastrophe precipitates tumorigenesis and cancer progression, and its induction constitutes a therapeutic endpoint.
Journal ArticleDOI
Evidence for Replicative Repair of DNA Double-Strand Breaks Leading to Oncogenic Translocation and Gene Amplification
Michael J. Difilippantonio,Simone Petersen,Hua Tang Chen,Roger D. Johnson,Maria Jasin,Roland Kanaar,Thomas Ried,André Nussenzweig +7 more
TL;DR: Mice deficient in both a nonhomologous end joining (NHEJ) DNA repair protein and the p53 tumor suppressor develop lymphomas at an early age harboring amplification of an IgH/c-myc fusion, report that these chromosomal rearrangements are initiated by a recombination activating gene (RAG)-induced DNA cleavage.
Related Papers (5)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more